Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0011854 (type 1 diabetes)
 20,749 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A 52-year-old Japanese woman being treated for type 1 diabetes showed forgetfulness and microcytic anemia with a high serum ferritin concentration. Serum and brain radiological examinations revealed aceruloplasminemia, which was confirmed by genetic testing. Aceruloplasminemia is characterized by the triad of retinal degeneration, diabetes mellitus, and adult-onset disorder of the extrapyramidal system. Though physicians should treat such patients earlier, it is difficult to diagnose the disease before the presentation of neurological symptoms. Despite the presence of microcytic anemia, aceruloplasminemia patients usually have a high serum ferritin concentration due to the complete absence of ceruloplasmin ferroxidase activity. Thus, physicians should consider aceruloplasminemia when diabetic patients present with microcytic anemia and a high serum ferritin concentration.
 ...
PMID:Criteria for early identification of aceruloplasminemia. 2172 62

In type 1 diabetes (T1D) therapy, continuous glucose monitoring (CGM) sensors, which provide glucose concentration in the subcutis every 1-5 min for 7 consecutive days, should allow in principle a more efficient insulin dosing than that based on the conventional 3-4 self-monitoring of blood glucose (SMBG) measurements per day. However, CGM, at variance with SMBG, is still not approved for insulin dosing in T1D management because regulatory agencies, e.g. FDA, are looking for more factual evidence on its safety. An in silico assessment of SMBG- vs CGM-driven insulin therapy can be a first step. Here we present a simulation model of T1D patient decision-making obtained by interconnecting models of glucose-insulin dynamics, SMBG and CGM measurement errors, carbohydrates-counting errors, insulin boluses time variability and forgetfulness, and subcutaneous insulin pump delivery. Inter- and intra- patient variability of model parameters are considered. The T1D patient decision-making model allows to run realistic multi-day simulations scenarios in a population of virtual subjects. We present the first results of simulations run in 20 virtual subjects over a 7-day period, which demonstrates that additional information brought by CGM (trend and hypo/hyperglycemic warnings) with respect to SMBG produces a statistically significant increment (about of 9%) of time spent by the patient in the euglycemic range (70-180 mg/dl).
 ...
PMID:Patient decision-making of CGM sensor driven insulin therapies in type 1 diabetes: In silico assessment. 2673 68